Myths by Daniel Clauw Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently #ACR24 Review Course @RheumNow https://t.co/7SGKMTC3HY https://t.co/0718sGsass

Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx

Should you worry about giving TNFi to RA pts after a cancer diagnosis? Medicare data with colorectal, lung, prostate Ca: TNFi pts survival no worse (numerically better) than csDMARDs Cancer pts deserve good RA treatment! #ACR24 ABST0202 Suarez-Almazor @MDAndersonNews @RheumNow… https://t.co/aR75hJQ6YK https://t.co/ptDYCsOpXN

ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl

Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/F9DOBLrjVq https://t.co/BtphAuEopA

54K Peptic Ulcers Annually (12.13.2024) https://t.co/18FiQx1YQA https://t.co/32UZi9XafS

Improvements in Pain and Fatigue in Bimekizumab Dr. Philip Mease discusses abstract 2368, presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/ON09z9yTuJ https://t.co/650TUdHwYm

Vaccine Responses:The DMARD Counts Dr. David Liew reviews abstracts 0247, 0248, 1988, 1009, reporting from Melbourne, Australia for the 2024 ACR Convergence meeting. https://t.co/0qDGRkT64B https://t.co/dO9EvhD1NE

How do you manage skin in Sscl? -RNA pol III + high risk for skin progression. -Limited+ low risk + stable Sscl no need for immunesuppresors. -Look for EF in pts with generalized morphea. -Ttnt of skin depending on other organ involvements. -If no Raynaud’s/hands spared think of… https://t.co/DZzhShKzS8 https://t.co/J9Qg1Lk2Wl

#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg